Roy Cleeland, Harry Albrecht, George Beskid, Kakong Chan, James Christenson, Nafsika Georgopapadakou, Dennis Keith, David Pruess, Edwina Squires, Chung Chen Wei, Manfred Weigele
{"title":"Dual-action antibacterials: A concept newly realized for antibacterial chemotherapy","authors":"Roy Cleeland, Harry Albrecht, George Beskid, Kakong Chan, James Christenson, Nafsika Georgopapadakou, Dennis Keith, David Pruess, Edwina Squires, Chung Chen Wei, Manfred Weigele","doi":"10.1016/0738-1751(89)90014-2","DOIUrl":null,"url":null,"abstract":"<div><p>Ro 23-9424 represents the culmination of an idea put forth by O'Callaghan et al<sup>4</sup> in 1976. They proposed that a cephalosporin could act as a carrier for a second antibacterial with the total molecule functioning as a single antibacterial until separated by opening of the ß-lactam ring by a ß-lactamase or, as we now know, the target penicillin-sensitive enzymes. It is important to note that in spite of the ester linkage, hydrolysis of Ro 23-9424 in animals to the components is minimal and the elimination kinetics are those of a single molecule with a pharmacokinetic profile of the cephalosporin component. The results of our preliminary toxicology studies in rats and dogs also suggest that this compound will have a safety profile similar to that of the cephalosporin component. This would allow parenteral administration of the quinolone component, fleroxacin, at a much higher dosage than is possible with the free quinolone.</p><p>Ro 23-9424 represents the first of a new class of antibacterials. The major constraint in designing new compounds within this class will only be the ingenuity of the pharmaceutical chemist.</p></div>","PeriodicalId":100101,"journal":{"name":"Antimicrobic Newsletter","volume":"6 8","pages":"Pages 61-65"},"PeriodicalIF":0.0000,"publicationDate":"1989-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0738-1751(89)90014-2","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobic Newsletter","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0738175189900142","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Ro 23-9424 represents the culmination of an idea put forth by O'Callaghan et al4 in 1976. They proposed that a cephalosporin could act as a carrier for a second antibacterial with the total molecule functioning as a single antibacterial until separated by opening of the ß-lactam ring by a ß-lactamase or, as we now know, the target penicillin-sensitive enzymes. It is important to note that in spite of the ester linkage, hydrolysis of Ro 23-9424 in animals to the components is minimal and the elimination kinetics are those of a single molecule with a pharmacokinetic profile of the cephalosporin component. The results of our preliminary toxicology studies in rats and dogs also suggest that this compound will have a safety profile similar to that of the cephalosporin component. This would allow parenteral administration of the quinolone component, fleroxacin, at a much higher dosage than is possible with the free quinolone.
Ro 23-9424 represents the first of a new class of antibacterials. The major constraint in designing new compounds within this class will only be the ingenuity of the pharmaceutical chemist.